Reproductive Health Planning for Patients with Multiple Sclerosis: A Clinician's Guide
Multiple sclerosis (MS) has a female predominance of approximately 3 to 1 and appears to be increasing among young women who are of reproductive age at the time of diagnosis. The impact of the disease and its treatment on the health of a pregnant mother and the developing fetus is a critical issue. While it may seem prudent to recommend that women discontinue disease-modifying therapy (DMT) before pregnancy or if a pregnancy is confirmed, this decision must be made on a case-by-case basis. Healthcare professionals require the latest information about DMT use during pregnancy, including available data on approved therapies and labeling recommendations that may influence this decision-making process.
This activity is designed to meet the educational needs of physicians, nurses and nurse midwives, advanced practice clinicians, and pharmacists, who manage patients with multiple sclerosis (MS).
Patricia K. Coyle, MD
Professor of Neurology
Director, MS Comprehensive Care Center
Stony Brook Neurosciences Institute
Stony Brook, NY
Patricia Melville, NP
Stony Brook Neurosciences Institute
Stony Brook, NY
Patricia Coyle, MD has disclosed the following financial relationships: Consulting Fees: Accordant, Alexion, Bayer, Biogen, Celgene, Genentech/Roche, Genzyme/Sanofi, GlaxoSmithKline, Mylan, Novartis, Serono, and TG Therapeutics; and Contracted Research: Actelion, Alkermes, Corrona LLD, Genentech/Roche, MedDay, NINDS, Novartis, and PCORI.
Patricia Melville has disclosed the following financial relationships: Consulting Fees: Sanofi-Genzyme; and Speakers Bureau: Biogen, Sanofi-Genzyme, Novartis, and EMD Serono.
June Halper, MSN, APN-C, MSCN, FAAN served as Planner for this activity and has disclosed no relevant financial relationships.
The following planners and managers have disclosed no relevant financial relationships: Joseph J. D'Onofrio, Frank Marino, Katherine Wandersee.
- Assess factors informing the continuation or discontinuation of disease-modifying therapy (DMT) for patients with MS who are pregnant or planning pregnancy.
- Evaluate treatment of MS for patients who require ongoing DMT during all or part of pregnancy.
- Analyze data and discuss outcomes from registries and databases of women exposed to various DMT agents during pregnancy.
- Discuss counseling strategies for women with MS and their partners to best control MS while optimizing a safe, healthy pregnancy.
The CMSC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The CMSC designates this enduring material for 1.0 continuing education nursing credit (1.0 in the area of pharmacology).
Upon successful completion of the activity, your CE credits will be submitted electronically to the NABP CPE Monitor service. For information about CPE Monitor, visit https://nabp.pharmacy/cpe-monitor-service/
The CMSC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria.
The CMSC designates this enduring material for 1.0 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.
Certificate of Participation for Other Healthcare Professionals
A Certificate of Participation will be given upon completion of the activity enabling participants to register their credit with the appropriate licensing boards or associations.
Commercial Support Statement
This webinar is supported by an educational grant from Bayer HealthCare Pharmaceuticals
Method of Participation
Follow these steps to earn CE credit:
- Read the target audience, learning objectives, and author disclosures.
- Study the educational content online
- Complete the post test and evaluation.
Statements of Credit are awarded upon successful completion of the post-test with a passing score of >75% and the evaluation.
Release Date: December 13, 2019
Valid for Credit Through: December 31, 2020
There is no fee to participate in this educational activity.
Disclosure of Unlabeled Use
This CE activity may contain discussion of published and/or investigational uses of agents that are not approved by the FDA. CMSC, Delaware Media Group, and the supporters do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of CMSC, Delaware Media Group, or the supporters.
Copyright © 2019, Delaware Media Group, Inc. All rights reserved. None of the contents of this webinar program may be reproduced in any form without prior written permission. The opinions expressed in this program are those of the faculty and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher, or the supporters.
If you have any questions about this CE activity, please contact the CMSC at email@example.com or 201-487-1050.